Business Context and Reporting Period
Ocular Therapeutix, Inc. (OCUL) filed a Form 8-K on July 17, 2020, to provide a business update and preliminary financial results for the quarter ended June 30, 2020. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing provides preliminary, unaudited revenue estimates for the quarter ended June 30, 2020. The company is currently finalizing its full financial results.
- Total Net Product Revenue: Approximately $1.6 million.
- DEXTENZA Revenue: Approximately $1.4 million.
- ReSure Sealant Revenue: Approximately $0.2 million.
The filing text does not provide clear values for profit, cash flow, margins, debt, or liquidity metrics for this period.
Material Changes
The filing does not explicitly state material changes compared to the prior comparable period, as it focuses on disclosing preliminary revenue figures for the current quarter.
Guidance, Outlook, and Risks
Management disclosed that the revenue figures are based on preliminary and unaudited information and management's estimates. These figures are subject to completion of the company's financial closing procedures. The company's independent registered public accounting firm has not conducted an audit or review of these estimated figures and does not express an opinion on them.
Investor Verification Checklist
- Verify the final audited revenue figures once the company completes its financial closing procedures for the quarter ended June 30, 2020.
- Review the full press release (Exhibit 99.1) for additional operational context not detailed in the 8-K summary.
- Monitor upcoming filings for complete financial statements including profit, cash flow, and balance sheet data.